To gain insights into the specificity of our Zr-89-labeled PSMA ligand, we conducted experiments to assess its effectiveness in recognizing its specific target, PSMA (prostate-specific membrane antigen), and in entering and binding to prostate cancer cells. Here, FOLH1 is linked to prostate carcinoma.